Pharma and Profits. John L. LaMattina

      

      Table of Contents

      1  Cover

      2  Title Page

      3  Copyright Page

      4  Dedication

      5  ACKNOWLEDGMENTS

      6  INTRODUCTION REFERENCES

      7  CHAPTER 1: THE $1000 PILL REFERENCES

      8  CHAPTER 2: ENTER THE PAYERS REFERENCES

      9  CHAPTER 3: PANDEMIC REFERENCES

      10  CHAPTER 4: FEDERAL INVESTMENT IN R&D REFERENCES

      11  CHAPTER 5: INSULIN REFERENCES

      12  CHAPTER 6: THE COSTLY ALZHEIMER’S DISEASE DRUG REFERENCES

      13  CHAPTER 7: GENE THERAPY REFERENCES

      14  CHAPTER 8: PROVING THE VALUE OF EXPENSIVE DRUGS REFERENCES

      15  CHAPTER 9: GENERIC DRUGS REFERENCES

      16  CHAPTER 10: ABOUT THOSE SOARING PHARMA PROFITS REFERENCES

      17  CHAPTER 11: SCHEMES TO LOWER DRUG PRICES REFERENCES

      18  FINAL THOUGHTS REFERENCES

      19  Index

      20  End User License Agreement

      List of Tables

      1 Chapter 3TABLE 3.1 mRNA timeline for Moderna and Pfizer

      List of Illustrations

      1 Chapter 5Graph 5.1 Lantus cost over time.

      2 Chapter 7Figure 7.1 Competition of spinal muscular atrophy drugs.

      3 Chapter 10Figure 10.1 Healthcare spending 2003–2018.

      Guide

      1  Cover Page

      2  Title Page

      3  Copyright Page

      4  Dedication

      5  ACKNOWLEDGMENTS

      6  INTRODUCTION

      7  Table of Contents

      8  Begin Reading

      9  FINAL THOUGHTS

      10  Index

      11  WILEY END USER LICENSE AGREEMENT

      Pages

      1  iii

      2  iv

      3  v

      4  ix

      5  x

      6  xi

      7  xii

      8  1

      9  2

      10  3

      11  4

      12  5

      13